Study finds risk of pulmonary embolism from ultrasound

Yale: Ultrasound is the most common technique for detecting a widespread cardiovascular condition: blood clots in the leg, otherwise known as deep vein thrombosis (DVT). But there’s a little known — yet serious — risk to using ultrasound to diagnose DVT, say Yale researchers in a new study published this week by Seminars in Thrombosis and Hemostasis.

Qantas first airline in the world to introduce exercise video to help prevent DVT

Melbourne: Qantas has become the first airline in the world to launch an exercise video on all its international flights to help prevent deep vein thrombosis (DVT). The four-minute exercise video was developed by academics at the University of Melbourne in a partnership with Physitrack, a global health-tech provider, and Sports Medicine Australia's official exercise technology partner. Sports Medicine Australia has endorsed the exercise video.

Venous Thrombosis Incidence Low, Largely Unchanged Despite Increase in Surgical Prophylaxis

JAMA: The incidence of venous thromboembolism (blood clot) complications after colorectal surgery was low and remained largely unchanged despite increased use of pre- and post-surgical prevention (prophylaxis) therapies, according to a report published online by JAMA Surgery. Preventing venous thromboembolism (VTE) in hospitalized patients has been promoted as a patient safety priority by a multitude of agencies.

Link between newer contraceptive pills and higher blood clot risks

Nottingham: A study led by academics at The University of Nottingham provides new evidence to confirm the link between newer contraceptive pills and higher risk of serious blood clots (known as venous thromboembolism or VTE). The results, published today in the BMJ, show that pills containing one of the newer types of progestogen hormone (drospirenone, desogestrel, gestodene, and cyproterone) are associated with an increased risk of VTE than pills containing older progestogens (levonorgestrel and norethisterone).

FDA approves anti-clotting drug Savaysa

FDA (US) approves anti-clotting drug Savaysa, drug approved to treat atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.